SURVODUTIDE 10mg

Note: Peptides will arrive in a powder form for maximum stability!!!

Survodutide (10mg) is a specialized research reagent utilized primarily to investigate multi-receptor metabolic signaling and systemic energy homeostasis. As a "dual agonist," it acts simultaneously on the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors. Dragon Pharma provides Survodutide 10mg at a purity level of 99%+, specifically for use in in-vitro laboratory experiments and preclinical animal models.

Overview

In the realm of metabolic research and cellular energetics, few compounds offer as much utility as Survodutide (BI 456906). Known scientifically as a dual-pathway incretin mimetic, this compound has become a fundamental tool for investigators exploring the synergistic effects of gut-hormone signaling and hepatic glucose regulation. Dragon Pharma provides Survodutide 10mg at a minimum purity of 99%, ensuring that researchers have access to a high-grade Research Peptide capable of producing reproducible and accurate data in complex biological models.

As scientific inquiry into obesity-related metabolic dysfunction, non-alcoholic steatohepatitis (NASH/MASH), and cardiovascular resilience expands, the need for reliable dual agonists like Survodutide has grown. This expanded profile examines the biochemical characteristics, structural integrity, and multifaceted research applications of Survodutide 10mg.

Molecular Characteristics and Chemical Profile

The structural integrity of Survodutide is what allows it to activate two distinct receptor pathways concurrently. It is a synthetic peptide engineered for enhanced stability and a prolonged biological half-life compared to endogenous ligands.

• Chemical Identity: Survodutide (GLP-1/Glucagon Receptor Dual Agonist)
• Molecular Formula: C192H289N47O61
• Molecular Weight: 4578.07 g/mol
• Purity: >99% (HPLC and Mass Spectrometry verified)
• Form: Lyophilized powder
• Manufacturer: Dragon Pharma

Research Applications

The peptide is utilized in various scientific investigative domains, including:

• Dual-Pathway Signaling: Mapping the coordinated activation of GLP-1 and Glucagon receptors.
• Hepatic Lipid Dynamics: Investigating the reduction of liver fat and modulation of lipid oxidation.
• Energy Expenditure: Assessing changes in metabolic rate and thermogenesis in animal models.
• Satiety Mechanisms: Studying central nervous system pathways related to food intake and appetite suppression.
• Fibrosis Modulation: Researching the impact of dual agonism on hepatic inflammatory signaling and scar tissue formation.

Pathway and Mechanistic Context

The core value of Survodutide 10mg in a laboratory setting is its ability to manipulate the Metabolic Balance by combining two complementary mechanisms. While GLP-1 agonists focus on insulin secretion and satiety, the inclusion of glucagon receptor agonism increases energy expenditure.

The GLP-1R / GCGR Signaling Axis

Upon activation by Survodutide, cells initiate a global shift in energy management:

1. GLP-1 Receptor (GLP-1R): Initiates insulinotropic effects and slows gastric emptying, primarily targeting satiety centers in the brain.
2. Glucagon Receptor (GCGR): Increases hepatic energy expenditure and promotes the "burning" of fatty acids, directly influencing metabolic flexibility.

Key Mechanistic Shifts:

• Enhanced Thermogenesis: Survodutide promotes a shift toward energy consumption, facilitating studies on weight modulation that go beyond simple caloric restriction.
• Lipid Metabolism: It inhibits the accumulation of fat in the liver by accelerating fatty acid oxidation.
• Glycemic Stability: Despite the inclusion of glucagon (traditionally a glucose-raiser), the GLP-1 component ensures balanced insulin production to maintain homeostasis in research models.

Primary Research Applications

1. Advanced Metabolic Syndrome and Obesity Research

Survodutide is heavily utilized in studies involving insulin resistance and weight-regulation failure. Because it mimics the metabolic benefits of both satiety and increased energy expenditure, it provides a unique framework for investigating the resolution of obesity-related comorbidities.

2. Hepatology and MASH (NASH) Studies

Known in research circles for its "liver-restorative" potential, Survodutide is used to observe how hepatic tissues adapt to chronic lipid stress. Investigators study changes in liver enzymes and the potential reversal of steatohepatitis in fibrotic models.

3. Cardiovascular and Ischemic Preconditioning

In cardiac research models, Survodutide is investigated for its potential to improve endothelial function. Research models focus on how dual-receptor engagement can protect tissues from oxidative stress and improve overall cardiovascular resilience.

Form and Analytical Testing

At Dragon Pharma, the commitment to scientific accuracy begins with a rigorous manufacturing process. Survodutide 10mg is produced under strict laboratory conditions to ensure the compound remains stable and bioactive.

• Lyophilization for Stability: The compound is supplied in a lyophilized (freeze-dried) form. This process removes moisture while preserving the molecular structure, which is critical for maintaining a long shelf life.
• Rigorous Analytical Verification: To guarantee a purity level of 99% or higher, every batch undergoes High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to confirm that the chemical signature matches the intended Survodutide profile.

Product Usage Disclaimer: This product is intended for laboratory and in-vitro research use only. It is not approved for human or veterinary application. Must be handled by qualified professionals. Not for drug, food, or cosmetic purposes. Misuse or misbranding is strictly prohibited.

Author:

All information was searched/edited by Dr. S. Edwin, and Dr. E. Croft who holds a doctorate from Case Western Reserve University School of Medicine